A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE.
Nature. 2021 Jan;589(7842):474-479. doi: 10.1038/s41586-020-3008-z. Epub 2020 Dec 9.
The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.
Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE.
Neuropharmacology. 2018 Nov;142:143-166. doi: 10.1016/j.neuropharm.2018.05.012. Epub 2018 Jun 5.
Therapeutic effect of psilocybin in addiction: A systematic review.
van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, Kramers K, Schellekens A, Somers M, Bossong MG, Batalla A.
Front Psychiatry. 2023 Feb 9;14:1134454. doi: 10.3389/fpsyt.2023.1134454. eCollection 2023.
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L.
JAMA Psychiatry. 2022 Oct 1;79(10):953-962. doi: 10.1001/jamapsychiatry.2022.2096.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Noller GE, Frampton CM, Yazar-Klosinski B.
Am J Drug Alcohol Abuse. 2018;44(1):37-46. doi: 10.1080/00952990.2017.1310218. Epub 2017 Apr 12.
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR.
J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.
Hallucinogens: an update.
Halpern JH.
Curr Psychiatry Rep. 2003 Oct;5(5):347-54. doi: 10.1007/s11920-003-0067-4.
Ecstasy (MDMA) dependence.
Jansen KL.
Drug Alcohol Depend. 1999 Jan 7;53(2):121-4. doi: 10.1016/s0376-8716(98)00111-2.
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.
Havel V, Kruegel AC, Bechand B, McIntosh S, Stallings L, Hodges A, Wulf MG, Nelson M, Hunkele A, Ansonoff M, Pintar JE, Hwu C, Ople RS, Abi-Gerges N, Zaidi SA, Katritch V, Yang M, Javitch JA, Majumdar S, Hemby SE, Sames D.
Nat Commun. 2024 Sep 20;15(1):8118. doi: 10.1038/s41467-024-51856-y.
The structural diversity of psychedelic drug actions revealed.
Gumpper RH, Jain MK, Kim K, Sun R, Sun N, Xu Z, DiBerto JF, Krumm BE, Kapolka NJ, Kaniskan HÜ, Nichols DE, Jin J, Fay JF, Roth BL.
Nat Commun. 2025 Mar 19;16(1):2734. doi: 10.1038/s41467-025-57956-7.
